Clinical intelligence that connects what specialists miss.
Ailva, a clinical intelligence platform for physicians, is built by Truthbound Industries Inc. in Austin, Texas.
The story
It takes an average of 17 years for a landmark clinical study to translate into standard practice. In that time, 1.16 million new biomedical articles are published every year, each one potentially containing the evidence a physician needs for the patient sitting in front of them. The gap between what medicine knows and what physicians can access at the point of care is not a failure of effort — it is a structural problem that grows wider every year.
The tools available today either retrieve and summarize — search engines with a summarization layer — or provide static expert-authored content with a search interface layered on top. Neither reasons across organ systems. Neither surfaces the connections that a brilliant integrative physician with perfect literature recall would see: the cardio-renal interaction that changes a drug choice, the drug-nutrient depletion that explains treatment resistance, the subgroup analysis from a nephrology trial that matters to a cardiologist.
Ailva was built to close that gap. Not a search engine. Not a chatbot. A clinical intelligence platform that understands how biological systems interconnect, and can synthesize patient-specific evidence with verified citations in seconds. Every claim is cited. Every citation is verified against 5 million indexed peer-reviewed papers. Every response is built for the physician who needs to act now and needs to trust what they are reading. See how Ailva works in practice.
Leadership
Sam Anderson
Founder & CEO
Building clinical intelligence that gives every physician the reasoning power of a world-class integrative specialist. Previously worked across full-stack engineering and health technology. Based in Austin, TX.
Kendall D. Price, MD
Chief Medical Officer
Dr. Kendall D. Price is a Stanford-trained physician, board-certified in both Anatomic Pathology and Hematopathology, with nearly two decades of diagnostic medicine leadership.
He completed his medical degree at the University of Illinois at Chicago, then trained at Stanford University consecutively as resident in Anatomic Pathology, Chief Resident, and fellow in Surgical Pathology, Immunopathology, Clinical Pathology, and Hematopathology — a breadth of subspecialty training virtually unmatched in the field. At Stanford he also served as a clinical teaching fellow and consulting pathologist to pioneering diagnostics and research organizations, including Diadexus and Pathwork Informatics.
From 2006 to 2024 Dr. Price served as Director of Hematopathology at Central Regional Pathology Laboratories, where he led complex diagnostic operations for nearly two decades. Concurrently, from 2017 to 2024 he served as Laboratory Director of Martell Diagnostic Laboratories, overseeing laboratory quality, compliance, and clinical decision-making across both institutions. He is co-founder of Price Pathology Solutions, LLP, and currently practices with SouthEastern Pathology, PC.
A published researcher with work spanning oncologic pathology, cardiovascular disease, and the metabolic origins of atherosclerosis, Dr. Price has contributed to peer-reviewed literature in journals including Archives of Pathology & Laboratory Medicine and Atherosclerosis. His research on hyperglycemia-induced ascorbic acid deficiency and endothelial dysfunction represents early, forward-looking work at the intersection of metabolic science and vascular pathology. His co-authored case report on CD56-positive enteropathy-associated T-cell lymphoma contributed to the diagnostic literature on rare and aggressive hematologic malignancies.
Dr. Price holds active medical licenses in Georgia, Alabama, and Minnesota, and is a graduate of Phillips Academy Andover and Amherst College, where he earned his bachelor's degree cum laude.
As Chief Medical Officer of Ailva, Dr. Price ensures that every clinical interaction on the platform meets the standard he has upheld across two decades of diagnostic practice: precision without compromise.
CME & Accreditation
Ailva is accredited by the Accreditation Council for Continuing Medical Education (ACCME) through iiCME. We are launching with CME activity tracks in three areas of clinical focus.
GLP-1 Therapeutics
Patient selection, comparative efficacy, cardiovascular and renal outcomes, and long-term management.
Breast Cancer Imaging
Screening guidelines, supplemental imaging modalities, and risk-based surveillance strategies.
Allergy & Immunology
Reviewed by Dr. Don A. Bukstein, MD — biologics, asthma outcomes, and shared decision-making.
Allergy & Immunology Track Reviewer
Don A. Bukstein, MD
Course Reviewer — Allergy & Immunology CME
Dr. Bukstein reviews the Allergy & Immunology CME curriculum on the Ailva platform. He brings nearly fifty years of leadership in clinical practice, medical education, electronic health records, and outcomes research, and is one of the most prolific voices in U.S. allergy and asthma education.
A graduate of Tulane University (BA, English Literature) and the University of Missouri–Columbia School of Medicine (MD, cum laude, 1977), he completed his pediatric residency at Children's Medical Center of Dallas and the University of Texas Southwestern, followed by fellowships in Allergy & Immunology and Pediatric Pulmonary Medicine at National Jewish Medical and Research Center and the University of Colorado Health Sciences Center. He is triple board-certified in Allergy/Immunology, Pediatrics, and Pediatric Pulmonary Medicine, and a Fellow of the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Allergy, Asthma & Immunology (ACAAI), and the American Thoracic Society (ATS).
Dr. Bukstein co-developed one of the earliest electronic medical record systems in the 1980s and served seventeen years as a pediatric intensive care physician before moving into outcomes research and physician education. As Vice President of THE Problem Based Learning Institute, he has trained over 75 cohorts of physicians and pharmaceutical speakers in interactive facilitation alongside President Dr. Ray Davis, and continues to deliver roughly 50 national and international presentations each year.
He has authored extensively on biologics, asthma outcomes, shared decision-making, pharmacoeconomics, and the integration of mental health into allergy care, with recent work appearing in The Journal of Allergy and Clinical Immunology in Practice.
About the name Ailva
Ailva is pronounced AYL-vah — two syllables, the first rhyming with hail, the second with the -vah in lava. It is a coined word, but it is rooted in an older one: the Old English ælf, the same stem that became the modern English elf.
Hundreds of years ago, Anglo-Saxons explained sudden, mysterious internal illnesses as the work of elf-shot — invisible arrows fired by unseen beings. Without microscopes, without sequencing, without any way of seeing viruses, genetic mutations, or the deep biological systems that drive disease, humans named the invisible cause they could not measure. The folklore was an attempt to make sense of patterns the eye could not reach.
The same tradition gives us the idea of elf-counsel — preserved in names like Alfred, literally “counsel of the ælf” — the notion that wisdom and insight could be granted from a source beyond ordinary sight.
Ailva sits at that meeting point. It is a clinical decision support tool that analyzes millions of data points to surface the deep biological connections inside the human body — connections that no single physician can hold in mind at once. It bridges the ancient idea of an unseen force uncovering hidden ailments with the modern reality of computation finding what humans cannot easily see. The name is a reminder of what the platform is for: turning what was once invisible into evidence a physician can act on.
What is the bench-to-bedside gap?
The bench-to-bedside gap is the delay between when clinical evidence is published and when it reaches routine medical practice. A landmark 2001 study by Balas and Boren estimated this gap at 17 years on average. During that time, patients who could benefit from published evidence are not receiving it. Ailva was built to compress this gap by giving physicians immediate access to synthesized, patient-specific evidence from over 16 million indexed peer-reviewed papers at the point of care.
What problem does Ailva solve?
Ailva solves the evidence-access problem in clinical medicine. Over 1.16 million biomedical articles are published every year, and no physician can track all the evidence relevant to their patients. Existing tools either retrieve from a single specialty or provide static expert-authored summaries. Ailva synthesizes evidence across 46 specialties, surfaces cross-system connections, and delivers patient-specific answers with verified citations in seconds.
Who built Ailva?
Ailva is built by Truthbound Industries Inc., based in Austin, Texas. It was founded by Sam Anderson, Founder and CEO, to close the gap between what medicine knows and what physicians can access at the point of care. The platform is free for all NPI-verified US healthcare professionals.